Table 3.
Echocardiography forty-eight hours after doxorubicin injection.
| C (n = 15) | GT (n = 15) | D (n = 15) | DGT (n = 15) | P i | P gt | P d | |
|---|---|---|---|---|---|---|---|
| HR (bpm) | 367 ± 9, 50 | 335 ± 10, 5 | 290 ± 9, 82 | 305 ± 9, 82 | 0,02 | 0,39 | <0,001 |
| LVDD/c (mm) | 20, 5 ± 0, 66 | 19, 9 ± 0, 73 | 20, 9 ± 0, 67 | 21, 0 ± 0, 67 | 0,55 | 0,69 | 0,29 |
| LVSD/c (mm) | 10, 1 ± 0, 72 | 9, 26 ± 0, 79 | 10, 7 ± 0, 74 | 9, 96 ± 0, 74 | 0,94 | 0,28 | 0,39 |
| PWT/c (mm/g) | 4, 39 ± 0, 17 | 4, 15 ± 0, 19 | 4, 76 ± 0, 17 | 3, 97 ± 0, 17 | 0,01 | 0,006 | 0,58 |
| RWT | 0, 42 ± 0, 02 | 0, 42 ± 0, 02 | 0, 46 ± 0, 02 | 0, 38 ± 0, 02 | 0,03 | 0,08 | 0,93 |
| LA/c (mm/g) | 10, 1 ± 0, 45 | 11, 1 ± 0, 48 | 12, 3 ± 0, 45 | 11, 3 ± 0, 48 | 0,004 | 0,93 | 0,01 |
| LA/AO (mm) | 1, 03 ± 0, 05 | 1, 15 ± 0, 05 | 1, 14 ± 0, 05 | 01, 15 ± 0, 05 | 0,26 | 0,22 | 0,27 |
| A (cm/s) | 78, 0 ± 4, 63 | 78, 4 ± 4, 88 | 49, 0 ± 4, 63 | 68, 4 ± 4, 88 | 0,05 | 0,03 | <0,001 |
| E (cm/s) | 88, 1 ± 9, 23 | 82, 7 ± 4, 46 | 72, 8 ± 4, 22 | 74, 2 ± 4, 48 | 0,44 | 0,65 | 0,001 |
| E/A | 1, 18 ± 0, 11 | 1, 11 ± 0, 12 | 1, 60 ± 0, 11 | 1, 09 ± 0, 12 | 0,07 | 0,02 | 0,09 |
| IRTc (m/s) | 4, 08 ± 0, 06 | 3, 99 ± 0, 06 | 4, 11 ± 0, 06 | 4, 08 ± 0, 06 | 0,60 | 0,30 | 0,35 |
| SF | 0, 51 ± 0, 02 | 0, 53 ± 0, 03 | 0, 49 ± 0, 02 | 0, 53 ± 0, 02 | 0,72 | 0,24 | 0,74 |
| LVMI | 1, 75 ± 0, 33 | 1, 71 ± 0, 39 | 1, 92 ± 0, 39 | 1, 72 ± 0, 39 | 0,37 | 0,19 | 0,35 |
Groups: C: control; GT: green tea; D: doxorubicin; DGT: doxorubicin+green tea. HR: heart rate in beats per minute; LVDD/c: left ventricular diastolic diameter corrected for body weight; LVSD/c: left ventricular systolic diameter corrected for body weight; PWT: posterior wall thickness; LA/c: left atrium diameter corrected for body weight; LA/AO: left atrium diameter corrected for aorta; A: wave ratio (represents the peak velocity of transmitral flow during atrial contraction); E: wave ratio (represents the peak velocity of early ventricular filling); IRTc: isovolumetric relaxation time; SF: shortening fraction. Values are expressed in mean ± standard deviation. P value: two-way ANOVA. Pi: P value of interaction; Pgt: P value of green tea; Pd: P value of doxorubicin. When we observed the interaction between factors doxorubicin and green tea, we considered Pi < 0, 05. HR: C ≠ GT, C ≠ D, and DGT ≠ D. PWT/c: D ≠ DGT. LA/c: D ≠ C, DGT ≠ D. RWT: D ≠ DGT. Comparisons without interaction: a wave and E/A: (GT + DGT) ≠ (C + D), A and E waves: (C + GT) ≠ (D + DGT).